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Abstract
Background: NANOS3 is a gene conserved throughout evolution. Despite the quite low conservation of Nanos
sequences between different organisms and even between Nanos paralogs, their role in germ cell development is
remarkably universal. Human Nanos3 expression is normally restricted to the gonads and the brain. However,
ectopic activation of this gene has been detected in various human cancers. Until now, Nanos3 and other Nanos
proteins have been studied almost exclusively in germ cell development.
Methods: Transgenic mice were generated by targeted insertion of a human Nanos3 cDNA into the ROSA26 locus.
The transgene could be spatiotemporally induced by Cre recombinase activity removing an upstream floxed STOP
cassette. A lung tumor model with ectopic Nanos3 expression was based on the lung-specific activation of the
reverse tetracycline transactivator gene, in combination with a tetO-CMV promoter controlling Cre expression.
When doxycycline was provided to the mice, Cre was activated leading to deletion of TP53 alleles and activation of
both oncogenic KRasG12D and Nanos3. Appropriate controls were foreseen. Tumors and tumor-derived cell cultures
were analyzed in various ways.
Results: We describe the successful generation of Nanos3LSL/− and Nanos3LSL/LSL mice in which an exogenous
human NANOS3 gene can be activated in vivo upon Cre expression. These mice, in combination with different
conditional and doxycycline-inducible Cre lines, allow the study of the role of ectopic Nanos3 expression in several
cancer types. The Nanos3LSL mice were crossed with a non-small cell lung cancer (NSCLC) mouse model based on
conditional expression of oncogenic KRas and homozygous loss of p53. This experiment demonstrated that ectopic
expression of Nanos3 in the lungs has a significant negative effect on survival. Enhanced bronchiolar dysplasia was
observed when Nanos3-expressing NSCLC mice were compared with control NSCLC mice. An allograft experiment,
performed with cell cultures derived from primary lung tumors of control and Nanos3-expressing NSCLC mice,
revealed lymph node metastasis in mice injected with Nanos3-expressing NSCLC cells.
Conclusions: A new mouse model was generated allowing examination of Nanos3-associated pathways and
investigation of the influence of ectopic Nanos3 expression in various cancer types. This model might identify
Nanos3 as an interesting target in cancer therapeutics.
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Background
NANOS3 is one of the three members of the mammalian
Nanos gene family. The functional role of Nanos pro-
teins has been studied mainly in Drosophila and other
lower organisms, in which Nanos proteins are essential
for anterior-posterior axis polarity, abdomen formation,
primordial germ cell migration, germ cell development
and survival, and neuronal homeostasis [1–7]. The key
role of Nanos proteins in germ cell development has also
been confirmed in mammals [8–10]. Both female and
male Nanos3 knockout mice lack germ cells [8]. Nanos3
expression in human embryonic stem cells is similarly
essential for maintaining normal germ cell numbers and
for the expression of genes required for pluripotency
and meiosis [11]. Nanos3 and Nanos proteins in general
have been identified principally as post-transcriptional
repressors [12, 13]. Nanos proteins exert this activity
mainly in concert with their conserved interaction part-
ner, Pumilio [12, 14, 15]. It is this Pumilio association
that generally confers mRNA target specificity.
Nanos proteins share a C-terminal zinc-finger domain,
which is the only Nanos domain evolutionarily
conserved from lower organisms to mammals [16]. The
Zf-nanos domain is also the most conserved region
between paralogs. Further, vertebrate and some inverte-
brate Nanos proteins share an additional short N-
terminal motif called NOT1 interacting motif (NIM)
[12, 16]. The strong conservation of the NIM and Zf-
nanos domains among vertebrate Nanos3 proteins
points to common interaction partners and functions
[12]. The NIM motif is responsible for the interaction of
Nanos with the CCR4-NOT deadenylation complex
[16–18], while the Zf-nanos domain mediates RNA
binding and interaction with the post-transcriptional
repressor Pumilio [19, 20]. The mRNA targets of the
Nanos/Pumilio complex are mainly recognized by the
presence of Nanos response elements (NREs) or
Pumilio-binding elements (PBEs), or both, in their
3’UTR sequences [12, 13, 15, 21].
On the other hand, there is emerging evidence for a
link between Nanos proteins and tumor progression and
cancer [12, 22–27]. Some of these studies revealed ec-
topic expression of Nanos in tumors [22, 24, 27]. Human
Nanos3 was reported to be overexpressed in non-small
cell lung cancer (NSCLC), and tumor cells with the
highest Nanos3 expression levels were located in cells at
the invasion front [27]. In vitro experiments confirmed a
role for Nanos3 in the migration and invasion of
cultured NSCLC cells [27]. Moreover, the finding that
Nanos3 influences epithelial-mesenchymal transition
(EMT) by attenuating CDH1 transcription, leading to
decreased E-cadherin expression, and by stimulating
vimentin protein expression, point at new mechanisms
of EMT regulation [27]. Further, the cBio Cancer
Genomics Portal (http://cbioportal.org) indicates that
gene amplification is the most common alteration of the
NANOS3 gene in various human cancer types. Despite
the putatively important roles of Nanos proteins in ma-
lignant cancers, the mechanisms and pathways involved
in ectopic Nanos expression are unknown. We present a
conditional mouse model that allows ectopic activation
of human NANOS3 in a tissue- and time-specific
manner. This model opens interesting avenues to
explore a new therapeutic target in cancer. The results
of our initial experiments using this mouse model in the
context of lung cancer support the idea that NANOS3
can be considered a tumor promoting gene.
Methods
Construction of transgenic Nanos3LSL mice
Human NANOS3 cDNA, encoding the longer isoform 2
(Additional file 1: Figure S1), was cloned into a Gateway
entry vector (pENTR3C) (Additional file 2: Figure S2). A
ROSA26-targeting strategy was used as described [28],
and detailed in Fig. 1 and Additional file 3: Figure S3.
Correctly targeted G4 ES cell clones were identified and
validated by PCR and Southern blotting, and used to
generate germline-transmitting Nanos3 conditional mice.
The primers are listed in Additional file 20: Table S1. ES
cells were aggregated with Swiss mouse embryos and
transferred into pseudo-pregnant Swiss mice. The
resulting Nanos3LSL/− mice were crossed with mice of the
C57BL/6 background (Janvier Labs, Saint-Berthevin,
France). The Nanos3LSL/− and Nanos3LSL/LSL mice are
available to the research community upon request.
Mouse tumor models
Mice expressing Cre recombinase under control of the
rat albumin promoter (Alb-Cre) [29], or the keratin-5
promoter (K5-Cre) [30], were both obtained from the
German Research Center for Environmental Health
(Neuherberg, Germany). For NSCLC mice on the basis
of LSL-KRasG12D and p53fl/fl alleles [31–33], a lung-
specific CCSP-rtTA+/−;TetO-Cre+/− Tet-on system was
used (kindly provided by Dr. A.-K. Perl, Cincinnati
Children’s Hospital Medical Center, Ohio, USA), and
combined or not with the Nanos3LSL allele. The progeni-
tor p53fl/fl mice were kindly provided by Dr. J. Jonkers
(Netherlands Cancer Institute, Amsterdam, The
Netherlands). The progenitor LSL-KRASG12D mice were
obtained from the NCI Mouse Repository (Frederick
National Laboratory for Cancer Research, Frederick,
Maryland, USA). To induce this NSCLC model, the
mice were fed normal food pellets supplemented with
doxycycline (625 mg/kg, Special Diets Services,
Tecnilab-BMI, Someren, The Netherlands) for two
weeks starting at the age of two weeks. At appropri-
ate times, tissues were dissected and fixed in 4%
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paraformaldehyde (PFA) overnight. The lungs were
first inflated with 4% PFA and then incubated in 4%
PFA for 2 h. For histology, 5-μm paraffin sections
were made throughout the entire lung. Genotyping
was done by PCR (for primers, see Additional file 20:
Table S1) on genomic DNA obtained from tails or
ears by standard methods.
All mice were bred and housed at the Vlaams Instituut
voor Biotechnologie (VIB, Ghent University) in a
specific-pathogen free facility. Mouse experiments were
Fig. 1 Nanos3 protein domains and sequences and generation of a Nanos3LSL transgene mouse. a. Human NANOS3 is transcribed in two protein-
encoding mRNAs. Both translated protein isoforms (173 and 192 amino acids; AA) include the conserved (CCHC)2 zinc-finger domain (Zf-nanos)
present in all Nanos proteins. In common with all vertebrate and a few invertebrate Nanos proteins, these isoforms have an additional N-terminal
NOT1 interacting motif (NIM). The only difference between these two isoforms is an insertion of 19 AA (grey rectangle) corresponding to the
retained intron #1 in the correct reading frame (Additional file 1: Figure S1). Such an intron is absent in mouse Nanos3 transcripts. The
percentages represent the sequence identity between the NIM or ZnF motif of human and mouse Nanos3 proteins. b. Representation of the
knock-in allele found in correctly targeted ES cells. Cre-mediated loxP recombination allows expression of Nanos3 isoform 2 and the IRES-eGFP
reporter under control of the ROSA promoter. LoxP sites are represented by triangles. SA, splice acceptor. c. Southern blot analysis of PCR
confirmed targeted ES cells showing an untargeted ES cell line (−) and three correctly targeted ES cell lines (1 to 3). d. PCR analysis to confirm
the presence of the NANOS3 and the IRES-eGFP cassette sequences in the three correctly targeted ES cell lines shown in C. A sample without a
cDNA template was used as a negative control and a previously tested ES cell line was used as a positive control
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performed in accordance with the Ethics Committee of
the Faculty of Science of Ghent University, and were
meeting the requirements of Directive 2010/63/EU. All
sections of this report adhere to the ARRIVE Guidelines
for reporting animal research [34]. A completed ARRIVE
guidelines checklist is included as Additional file 21. The
Animal Facility Procedures and Licenses of the Inflam-
mation Research Center (Ghent University and VIB,
Ghent, Belgium) are overviewed in Additional file 22.
Immunohistochemistry
Liver, skin and lung sections were deparaffinized,
rehydrated and blocked by routine procedures. A citrate
buffer was used for antigen retrieval in a 2100 Retriever
pressure cooker (PickCell Laboratories, Amsterdam, The
Netherlands). Tissues were incubated overnight at 4 °C
with antibody against eGFP (Cell Signaling, Danvers,
Massachusetts, US; 1:200), Nanos3 (Proteintech, Chi-
cago, USA; 1:200), Vimentin (Gentaur, Kampenhout,
Belgium, 1:6000), CC10/CCSP (Millipore, Darmstadt,
Germany; 1:4000), SPC (Millipore; 1:4000), E-cadherin
(BD Biosciences, New Jersey, US; 1:500), or pan-
cytokeratin (Abcam, Cambridge, UK; 1:1800), in PBS
containing 5% goat serum and 1% BSA. Slides were in-
cubated with appropriate secondary antibodies (Dako,
Glostrup, Denmark) and specific signals were enhanced
by use of the ABC-kit (Vector).
Western blotting
Liver tissues were lysed in Laemmli buffer (50mM Tris-
HCl pH 6.8, 10% glycerol and 2% SDS) supplemented with
protease inhibitors (Complete Mini, Roche) for 0.5 h on
ice. Lysates were sonicated (Sonics vibra cell™) for 1min
with one-second intervals, after which cell debris was
removed by centrifugation. Lung tissues, lung tumor-
derived cells and allografts were lysed in a lysis buffer con-
taining 10mM Tris pH 8.0, 150mM NaCl and 0.5% NP-
40 supplemented with protease inhibitors for 0.5 h at 4 °C.
Equal amounts of protein, measured by the DC protein
assay kit (Bio-Rad), were separated in a 12% SDS-PAGE
gel. Blots were incubated overnight at 4 °C with anti-eGFP
antibody (Roche; 1:1000), anti-actin antibody (MP bio-
medicals; 1:10,000), anti-β-actin antibody (BA3R, Thermo-
Fisher, Massachusetts, USA 1:1000) or G379, a home-
made polyclonal Nanos3 antibody raised in rabbits against
peptide NH2-KKLVRPDKAKTQDTGH-COOH (1:500),
or a Nanos3-specific antibody (Proteintech, 1:1000). After
incubation with HRP-coupled secondary antibody (Dako),
blots were visualized on film (GE Healthcare) using ECL
(Thermo Scientific).
RNA isolation and RT-qPCR
Tissue and cell lysates were homogenized in TRIZOL
(Invitrogen) with the Polytron PT 1600E (Kinematica
AG) and/or by passing the sample ten times through a
20-gauge needle. The RNeasy Plus Mini kit (Qiagen) was
used to isolate total RNA. cDNA was prepared using a
SuperScript™ III First-strand Synthesis system (Thermo
Fisher). Expression levels of the genes of interest and
reference genes were analyzed by real-time quantitative
PCR using the SensiFast SYBR No-ROX kit (GC
Biotech). Gene expression was normalized to reference
genes using qbase+ (Biogazelle) [35]. The primers are
listed in Additional file 23: Table S2.
Measurement of bronchiolar hyperplasia and tumor
volumes
H&E sections of the lungs of both control and
Nanos3LSL mice of the NSCLC model were scanned with
the Axio Scan.Z1 Slide Scanner. To measure the extent
of bronchiolar hyperplasia, the surrounding perimeter of
bronchioles was manually drawn, and areas were
measured using Volocity. The area inside the bronchi-
oles was measured using the magic wand ROI tool of
Volocity. The extent of bronchiolar hyperplasia was
estimated by subtracting the inside area of the bronchi-
ole from the area of the complete bronchiole. This value
was divided by the perimeter of the bronchiole.
Total tumor volumes were estimated using ImageJ
1.51j. A program was written to calculate the tumor
percentage making use of a classifier model manually
trained on H&E sections of both control and Nanos3-
expressing mice, using the Trainable Weka Segmenta-
tion plugin in ImageJ.
Lung tumor-derived cell cultures
Primary lung tumor cell cultures were derived from the
lungs of one control (LSL-KRasG12D;p53fl/fl;CCSP-
rtTA+/−;TetO-Cre+/−) and one Nanos3 (Nanos3LSL/−;
LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/−)
NSCLC mouse. After dissection, the lungs were incu-
bated in PBS with geneticin (250 μg/ml) for 1 h at room
temperature. The lungs were fragmented and dissociated
by sterile methods. Dissociation was at 37 °C for 2 to 3 h
in DMEM containing 250 μg/ml gentamycin, 0.5%
glucose, 0.125 units/ml dispase II, 0.2% collagenase, and
10% FCS. The resulting cell suspension was consecu-
tively run through 70-μm and 40-μm cell strainers, and
then centrifuged at 400 x g for 7 min at 4 °C. Cell pellets
were suspended in 1 ml of Ammonium-Chloride-
Potassium lysing buffer (Lonza) for 5 min. Cells were
washed with PBS and seeded in RPMI medium supple-
mented with 10% FCS and non-essential amino acids.
Soft agarose assay
Anchorage-independent growth was determined by
seeding single-cell suspensions in medium containing
0.35% agarose (Bioline) on top of a 0.76% agarose layer.
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An additional top-agar layer was added after one week.
After 14 days, pictures were taken with a Leica DC300F
digital microscope camera using XnView software, and
colonies were counted with Volocity. Experiments were
performed in duplicate and the mean value was used for
further analysis.
Allograft experiment
Athymic mice (NMRI-Foxn1nu/nu; Envigo, Horst, The
Netherlands) of 5 weeks old were subcutaneously
injected with cell cultures derived from the lungs of a
control (LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-
Cre+/−) or a Nanos3 (Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;
CCSP-rtTA+/−;TetO-Cre+/−) NSCLC mouse, using five
replicates per cell culture. Per mouse, 2.5 million tumor
cells (in 100 μl PBS) were mixed with an equal volume
of Matrigel (Corning® Matrigel® Basement Membrane
Matrix, VWR) before injection. The length (L), width
(W) and height (H) of the tumors were measured twice
a week with a caliper till the tumor reached about 1250
mm3, or otherwise for a period of maximum 70 days.
Tumor volumes were calculated by using the following
equation: (π/6) x L x W x H.
Statistical analysis
The data were analyzed with GraphPad Prism 7. An un-
paired Student’s t-test was used to analyze RT-qPCR
data. A log-rank (Mantel-Cox) test was performed to
analyze the survival curves.
Allograft data were analyzed as repeated measure-
ments using the residual maximum likelihood (REML)
approach as implemented in Genstat v18 [36]. Briefly, a
linear mixed model with cell cultures, time and cell cul-
tures x time interaction as fixed terms, and subject.time
used as residual term, was fitted to the data. Times of
measurement were set at equal intervals and an autore-
gressive correlation structure of either order 1 (AR1) or
order 2 (AR2) was selected as best model fit, based on
the Akaike Information Coefficient. Significance of the
fixed terms and changes in differences across time were
assessed by an F-test.
Results
Novel mouse model with conditional ectopic expression
of human Nanos3
We used an improved transgenesis system, based on
cointegration of the transgene of interest with a floxed
STOP (LSL) cassette in the Rosa26 locus [28], to
efficiently create our transgenic mouse line. A Gateway
compatible entry clone containing human NANOS3
cDNA, encoding the longest Nanos3 isoform 2 (Fig. 1a;
Additional file 1: Figure S1 and Additional file 2: Figure S2)
but lacking the 3’UTR sequence, was inserted into the pre-
viously described pROSA26 destination vector (Additional
file 3; Figure S3) [28]. The NANOS3 cDNA was inserted
between a PGK-neo-3xpA (STOP) cassette (in which the
neomycin resistance (neor) gene is driven by the phospho-
glycerine kinase (PGK) promoter) and an internal riboso-
mal entry site (IRES) is placed ahead of an enhanced green
fluorescence (eGFP) sequence. This bicistronic vector al-
lows simultaneous expression of the gene of interest and
the eGFP reporter protein, but only in cells expressing Cre
recombinase. The resultant targeting vector was intro-
duced into F1 hybrid derived (G4) embryonic stem (ES)
cells. The primary ES cell colonies were screened by posi-
tive selection (neomycin resistance) and negative selection
(diphtheria toxin A resistance). Further screening and val-
idation was done by Southern blotting and PCR analyses
(Fig. 1c, d). Correctly targeted ES cells were used to gener-
ate conditional transgenic Nanos3 mice. In this transgenic
line, Cre-dependent expression of NANOS3 and eGFP is
driven by the ROSA26 promoter, which provides a
moderate level of expression. We refer to these new trans-
genic mice as Nanos3LSL mice, namely, Nanos3LSL/LSL
(homozygous) and Nanos3LSL/− (heterozygous).
Depending on the Cre mouse line that is bred with the
Nanos3LSL transgenic line, Nanos3 expression is ubiqui-
tous, tissue-specific, or developmental-stage specific. To
test the functionality of the expression system, we ini-
tially crossed the Nanos3LSL mice with the Sox2-Cre
transgenic mouse line [37]. Interestingly, this experiment
showed that transgenic expression of Nanos3 in all
tissues was embryonically lethal (data not shown). Next,
the Nanos3LSL mice were crossed with an albumin-Cre
(Alb-Cre) transgenic line [29]. Cre-dependent expression
of Nanos3 and eGFP specifically in the liver was con-
firmed by genotyping, western blotting and RT-qPCR,
which proved the reliability of the induction system
(Fig. 2a, b). Similarly, we made use of a K5-Cre line [30],
to obtain epidermis-specific Cre expression and checked
Nanos3 and eGFP expression in the skin by RT-PCR
and immunohistochemistry. This confirmed the epider-
mis-specific expression of Nanos3 in line with the
tissue-specific activation of the Cre recombinase (Fig.
2c, d and Additional file 4: Figure S4 for higher mag-
nifications). Both experiments demonstrate the func-
tionality of the conditional Nanos3 expression system,
although both the Alb-Cre;Nanos3LSL and the K5-Cre;
Nanos3LSL mouse models did not show any evidence
of Nanos3-induced pathology.
Ectopic human Nanos3 expression in a NSCLC model
shortens survival
The expression of the NANOS3 gene in our transgenic
mouse model can also be controlled by using the Tet-on
system [38]. In that case, expression of the Cre recom-
binase is controlled by the reverse tetracycline transactiva-
tor (rtTA). In the presence of doxycycline (dox), rtTA
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binds the tetracycline operator (tetO) preceding the Cre
recombinase gene, allowing transcription of the latter.
Spatiotemporally controlled Cre expression can be ob-
tained by driving rtTA expression by appropriate pro-
moter sequences. We used the Nanos3LSL mice in
combination with the established LSL-KRasG12D;p53fl/fl
lung cancer model [39–41]. In our setup, the rtTA trans-
gene was driven by the rat CCSP promoter (Fig. 3a), which
is transcriptionally active in club cells in the bronchioles
and in type-II cells in the alveoli. Doxycycline-
supplemented food was administered for two weeks,
starting at the time of weaning.
Transgenic NSCLC mice in which expression of
Nanos3 was induced (Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;
CCSP-rtTA+/−;TetO-Cre+/−) are hereafter referred to as
Nanos3 NSCLC mice. Those in which the Nanos3 trans-
gene was not present (LSL-KRasG12D;p53fl/fl;CCSP-
rtTA+/−;TetO-Cre+/−) are referred to as control NSCLC
mice. These Nanos3 NSCLC mice are characterized by




Fig. 2 Analysis of the livers of Alb-Cre;Nanos3 mice (a, b) and skin from K5-Cre;Nanos3 mice (c, d) with expression of heterozygous or
homozygous Nanos3LSL alleles. Western blot (a) and RT-qPCR analysis (b) of liver lysates from control mice and mice with liver-specific expression
of heterozygous or homozygous ectopic Nanos3LSL alleles. c. RT-qPCR analysis was done to check for eGFP and NANOS3 RNA expression in RNA
lysates of skin from a Nanos3LSL/−;K5-Cre+/− mouse and a Nanos3LSL/−;K5-Cre−/− mouse. CNRQ, calibrated normalized relative quantity; error bars,
SEM; n = 3. b and c. Gene expression was normalized to reference genes (Tbp and Hmbs) using qbase+ (Biogazelle) [35]. d. eGFP expression in
skin sections from a Nanos3LSL/−;K5-Cre−/− mouse and a Nanos3LSL/LSL;K5-Cre+/− mouse was analyzed by immunohistochemical staining.
Bars; 100 μm
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type-II cells of the alveoli of the lung. In general, ectopic
expression involves abnormal gene expression in a cell
type, cell tissue type, or developmental stage in which
the gene is not usually expressed [42]. In our model, we
overexpressed Nanos 3 in the lungs, where it is normally
not expressed, to investigate its potential tumor promot-
ing role in lung cancer.
Additionally, in these models, Nanos3-expressing mice
express only one exogenous human NANOS3 allele.
Homozygous expression of this transgene was not pos-
sible in a straightforward way since the mutant KRAS al-
lele was located on chromosome 6 as is the ROSA locus
where the NANOS3 transgene was inserted. Lung lysates




Fig. 3 Nanos3 and eGFP expression in the lungs of transgenic mice. a. Scheme of inducible Nanos3 expression in the lungs. The club cell
secretory protein (CCSP) promoter, active in club cells and type-II alveolar cells, leads to transcription of the reverse tetracycline transactivator
gene (rtTA). In the presence of doxycycline (Dox), rtTA binds the tetracycline operator (tetO) in the tetO-CMV promoter, leading to Cre
recombinase expression. Cre recombinase mediates recombination between loxP sites and thereby deletes the floxed STOP cassette (LSL) and
allows transcription of Nanos3 and enhanced green fluorescent protein (eGFP). IRES: internal ribosomal entry site. To induce transgene expression
both control and Nanos3 NSCLC mice were fed doxycycline-containing food and killed about 38 days after Dox induction. b. Total lung lysates of
two Cre-negative control mice, three Cre-positive control NSCLC mice (LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/−) and three Nanos3
overexpressing NSCLC mice (Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/−) were tested for Nanos3 and the associated eGFP
expression by western blotting. Actin was used as a loading control. c. RNA prepared from total lung lysates of control and Nanos3-
overexpressing mice was used to detect eGFP and Nanos3 transcripts by RT-qPCR. CNRQ, calibrated normalized relative quantity; error bars, SEM;
n = 3, **: P ≤ 0.01 and ****: P ≤ 0.0001. Gene expression was normalized to reference genes (rpl13A and hprt1) using qbase+ (Biogazelle) [35].
d. Lung tumor sections of control NSCLC mice and Nanos3-overexpressing NSCLC mice (Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-
Cre+/−) were stained with a GFP- and a Nanos3-specific antibody. Bars: 5 mm for the total lungs, 500 μm for the magnifications of the eGFP
staining and 200 μm for the magnifications of the Nanos3 staining
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Nanos3 and eGFP expression to assess the functionality
of the ROSA26 transgenic expression cassette. As
expected, RT-qPCR, western blotting and immunohisto-
chemical analysis confirmed Nanos3 and eGFP expression
in the lungs of the Nanos3 NSCLC mice (Figs. 3b-d). A
more detailed analysis of eGFP expression, which can be
used in our model as a reliable marker for ectopic Nanos3
expression, showed eGFP expression in both adenocarcin-
oma and bronchiolar neoplasia and confirmed the tran-
scriptional activity of the CCSP promoter in the club cells
of the bronchioles and in type-II cells of the alveoli. Inter-
estingly, eGFP expression could be detected in the stromal
cells of tumors derived from alveolar tissue, but could not
be detected in stromal cells of tumors derived from bron-
chiolar tissue (Additional file 5: Figure S5).
We found that transgenic control NSCLC mice devel-
oped lung tumors resembling those seen in bronchiolo-
alveolar carcinoma (BAC), which in humans was
recently named lepidic carcinoma [43]. These tumors re-
main noninvasive without any stromal reaction. Grelet
et al. [27] demonstrated that Nanos3 enhances the inva-
sion rate of cultured NSCLC cells and is involved in
EMT regulation. In line with this, we wondered whether
Nanos3 overexpression affects tumor progression in
vivo. In our NSCLC mouse model, no metastasis was
observed regardless of Nanos3 expression. However,
mice overexpressing Nanos3 died significantly earlier
(Fig. 4a). When comparing male and female control
NSCLC mice with, respectively, male and female Nanos3
NSCLC mice, a significant difference was seen only be-
tween the female mouse populations. While female con-
trol NSCLC mice (n = 13) had a median survival of 61
days after dox induction, that of female Nanos3 NSCLC
mice (n = 13) was only 37 days after dox induction (P <
0.001). On the other hand, male control NSCLC mice
(n = 7) had a median survival of 60 days after dox induc-
tion, whereas male Nanos3 NSCLC mice (n = 10)
showed a similar median survival of 53 days after dox in-
duction. In both male and female mice, no metastases
were observed, and a significant difference between con-
trol and Nanos3 NSCLC mice was seen only for female
populations. Further experiments were therefore done
solely with female mice.
Both control and Nanos3 NSCLC mice were killed
about 40 days after dox induction, and their lungs were
histologically examined. Different stages of tumor pro-
gression were observed (Fig. 4b). Alveolar hyperplasia,
premalignant atypical adenomatous hyperplasia (AAH)
and adenocarcinoma were observed in the alveolar spaces
(Fig. 4b, a-c and f-h; and Additional file 6: Figure S6 for
higher magnifications). Focal and papillary hyperplasia
were observed in the bronchioles (Fig. 4b, d, e and i, j; and
Additional file 7: Figure S7 for higher magnifications).
While the lungs of both control and Nanos3 NSCLC mice
showed bronchiolar hyperplasia compared to the lungs of
tumor-free, Cre-negative control mice, hyperplasia was
more prominent in the Nanos3 NSCLC mice (Fig. 5). The
lung tumor mass in Nanos3 and control NSCLC mice was
measured by image analysis on several H&E slides
throughout the entire lungs (see Methods). However,
there was no significant difference in tumor mass between
the genotypes (Additional file 8: Figure S8).
The bronchioles, including the hyperplastic tissues,
stained positive for the Club Cell 10-kDa protein (CC10)
and largely negative for Surfactant Protein C (SPC)
(Fig. 6; Additional file 9: Figure S9 for CC10 staining,
and Additional file 10: Figure S10 for SPC staining). In-
versely, the adenocarcinomas were SPC-positive and
CC10-negative. The bronchiolar hyperplasias also
stained positive for Sox2, an important transcription
factor for differentiation of ciliated, club and goblet cells
in postnatal bronchioles [44] (Fig. 6). Most of the
adenocarcinomas were mainly Sox2-negative but some
were completely or partially Sox2-positive (Fig. 6 and
Additional file 11: Figure S11). These results indicate
that the bronchiolar hyperplastic lesions arose from
transformed club cells, while the adenocarcinomas origi-
nated mainly from transformed alveolar type-II cells.
Several EMT-related immunohistochemical stainings
were performed on lung sections of both types of
NSCLC mice, with and without Nanos 3 expression. E-
cadherin staining showed no evidence of downregulation
upon Nanos3 expression in lungs of Nanos3 NSCLC
mice (Additional file 12: Figure S12). Moreover, staining
for the EMT marker vimentin showed no evidence of
upregulation upon Nanos3 expression in this mouse
cancer model (Additional file 13: Figure S13). These data
indicate that Nanos3 overexpression in this NSCLC
model did not influence the expression level of the
EMT-related genes, E-cadherin and vimentin.
The effect of Nanos3 expression on the behavior of
cultured lung tumor cells
To further investigate the effect of ectopic Nanos3
expression on tumor progression, cell cultures were
derived from primary lung tumors from either a con-
trol NSCLC or a Nanos3 NSCLC mouse. These cell cul-
tures will be further referred to as LuTDco and
LuTDNa3 cell cultures, respectively.
Six LuTDco and five LuTDNa3 cell cultures were
validated for ectopic Nanos3 and eGFP expression by
western blotting and qRT-PCR analysis (Additional file 14:
Figure S14). Both experiments showed expression of
Nanos3 and eGFP in LuTDNa3 cells, whereas control
LuTDco cells did not. A soft agar colony formation assay
was then used to measure anchorage-independent
growth in vitro. LuTDNa3 cell cultures had a higher
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anchorage-independent colony formation potential than
LuTDco cells (Fig. 7a).
Further, three LuTDco and three LuTDNa3 cell cul-
tures were analyzed in a mouse allograft experiment,
using subcutaneous injection into athymic mice (Fig. 7b)
. In general, ectopic tumors originating from LuTDNa3
and LuTDco cultures grew at similar rates. NANOS3
and eGFP mRNA expression were clearly detected in the
ectopic tumors originating from the LuTDNa3 cells but
were absent in tumors from the LuTDco cells
(Additional file 15: Figure S15).
Small tumor nodules were detected on the lungs of
several mice injected subcutaneously with LuTDNa3 or
LuTDco cell cultures. However, metastasis formation
was not consistently observed in all mice injected with a
particular cell culture. Furthermore, no significant
difference in lung metastasis was observed in mice sub-
cutaneously injected with either LuTDco or LuTDNa3
A
B
Fig. 4 Female mice developing NSCLC die significantly earlier when ectopically expressing Nanos3. a. Kaplan-Meier curves for the KRasG12D,p53−/−
lung cancer model with or without ectopic Nanos3 expression. A1. The survival curves of control NSCLC mice compared to Nanos3 NSCLC mice.
A2–4. Subdivision of the female (_F) and male (_M) control and Nanos3-expressing NSCLC mice. A significant difference was observed in survival
between the female control and Nanos3 expressing mice (a2) and between Nanos3-expressing female and male mice (a4). ns: not significant,
**: P≤ 0.01 and ***: P ≤ 0.001. b. Microscopic images of H&E-stained lung sections from Nanos3-overexpressing (a-e) and control (f-j) NSCLC mice.
These sections show alveolar hyperplasia (a and f), atypical adenomatous hyperplasia (b and g) and adenocarcinoma formation (c and h). In the
bronchioles, focal hyperplasia (d and i) and papillary hyperplasia (e and j) of bronchiolar epithelial cells is seen. Bar: 50 μm
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cells. In contrast, the axillary lymph nodes of mice sub-
cutaneously injected with the LuTDNa3 cell cultures F5
and D10 were visibly enlarged compared to those from
the other mice. For ethical reasons mice injected with
LuTDNa3 G11 were sacrificed two to three weeks earlier
than those injected with the other LuTDNa3 cell cul-
tures, which might explain why their lymph nodes were
not swollen. Histological analysis showed that the axil-
lary lymph nodes of the LuTDNa3-injected mice (F5 and
D10), but not those of LuTDco-injected mice, harbored
genuine metastases (Fig. 8).
A majority of these lymph node metastases in
LuTDNa3-injected mice demonstrated clear evidence of
epithelial differentiation with typical histology and
strong positivity for pan-cytokeratin and E-cadherin
(Additional file 16: Figure S16), coinciding with eGFP
positivity (Fig. 8; Additional file 17: Figure S17 for higher
magnifications). In contrast, the lymph nodes of mice
injected with LuTDco cultures looked largely normal.
To gain more insight into the mechanism why sub-
cutaneous injection of LuTDNa3 cell cultures resulted in
lymph node metastasis, we assessed by qRT-PCR the ex-
pression level of several migration and invasion markers
in the primary lung tumor-derived cell lines LuTDco
and LuTDNa3. Intriguingly, this experiment showed no
significant differences between LuTDco and LuTDNa3
cell lines in the expression levels of several EMT-
related genes, namely Cdh1, Vim, Cdh2, Fn, Snai1
and Zeb1, at least not at the mRNA level
(Additional file 18: Figure S18). This suggests that
other Nanos3-induced pathways are involved in the
increased lymph node metastasis of LuTDNa3 cells.
On the contrary, we previously reported that Nanos3
overexpression in human NSCLC cell lines Calu-1 and
SK-LU-1 enhanced their invasiveness by up-regulating
EMT and wondered whether differences in the level of
Nanos3 overexpression could explain this discrepancy be-
tween human and mouse lung tumor-derived cells. We
thus performed Western blot analysis on lysates of two
LuTDco (B5, B6) and two LuTDNa3 cell cultures (D10,
F5) and compared the expression levels of Nanos3 with
those in lysates of Nanos3-overexpressing human Calu-1
and SK-LU-1 cells. This experiment demonstrated higher
normalized Nanos3 expression levels in the mouse tumor
derived LuTDNa3 cell lines, compared to the Nanos3-
overexpressing human cell lines Calu-1 and SK-LU-1
Fig. 5 Ectopic Nanos3 expression aggravates bronchiolar hyperplasia in NSCLC mice. a. Our mouse model for NSCLC showed bronchiolar
hyperplasia compared to Cre-negative control mice. Ectopic Nanos3 overexpression strongly enhanced this bronchiolar phenotype.
Representative sections are shown. b. Three Cre-negative mice (Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre−/−), five Cre-positive
control NSCLC mice (LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/−) and five Nanos3 NSCLC mice (Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;CCSP-
rtTA+/−;TetO-Cre+/−) were analyzed. The ratio of bronchiolar hyperplasia to the perimeter of the bronchiole was measured in four
randomly chosen bronchioles per mouse. The plot shows the average for each mouse. Error bars, SEM; *: P ≤ 0.05 and **: P ≤ 0.01.
Bars: 100 μm
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(Additional file 19: Figure S19), and indicates that higher
Nanos3 expression levels do not invariably correlate with
higher invasion and migration properties.
Discussion
We generated a conditional hNanos3-expressing mouse
model, Nanos3LSL. For this transgenesis, we used a
cDNA, encoding the longest isoform of human Nanos3
(192 AA). Compared to the shorter isoform and the
mouse Nanos3, this isoform has an insert of 19 AA
encoded by a retained intron (Fig. 1a; Additional file 1:
Figure S1 and Additional file 2: Figure S2). We chose
this human cDNA because this transcript has been
annotated in the curated human consensus coding
sequence set (CCDS) [45], and because of the reported
relevance of ectopic Nanos3 expression in human
cancers [12, 27]. In the background of several mouse
Cre-lines, the Nanos3LSL mice gave reliable transgene
expression fully dependent on the specificity of the Cre
recombinase activity. As we found that transgenic
expression of Nanos3 in all tissues was embryonically
lethal, we opted for the Tet-on system [38], in order to
spatiotemporally control Cre expression. This approach
is also ideal for combining inducible Nanos3 expression
with inducible loss of a tumor suppressor gene or activa-
tion of an oncogene, or both, and makes it possible to
analyze the influence of ectopic Nanos3 expression in a
wide range of cancer models. Previous reports had
already linked ectopic expression of Nanos1 and Nanos3
to NSCLC [24, 27]. More specifically, the germline gene
Nanos3 is not expressed in healthy adult somatic tissues,
like normal lung tissue, with the exception of testis and
brain. However, NANOS3 was found to be expressed in
the nucleus and/or cytoplasm of human NSCLC tumor
cells independently of their histological subtype.
Additionally, stronger staining was frequently observed
at the invading front of tumor clusters, especially in
squamous cell carcinomas [27]. Therefore, in a first at-
tempt to investigate the in vivo role of ectopic Nanos3
expression in tumor progression, we crossed our
Nanos3LSL mouse with a NSCLC mouse model based on
LSL-KRasG12D and p53fl/fl alleles [39–41]. Several alter-
native approaches are of course feasible for lung cancer
models, including viral transduction of the Cre gene into
the respiratory system [46, 47].
The functions of the Nanos/Pumilio complex in germ
cell development, including prevention of apoptosis and
inhibition of precocious PGC differentiation [3], seem to
be highly conserved from flies to mammals, as elegantly
demonstrated by the Saga group [9]. The remarkable mi-
gratory behavior of PGCs under the influence of Nanos
can be considered an example of non-pathological inva-
sive behavior. Grelet et al. [27] linked Nanos3 to EMT in
human NSCLC cell cultures in which Nanos3 overex-
pression stimulates EMT, whereas its silencing induces
mesenchymal–epithelial transition (MET). As invasion
Fig. 6 Heterogeneous CC10, SPC and Sox2 staining of bronchioles and adenocarcinomas in NSCLC. Sections of bronchioles (arrowheads) and
adenocarcinomas (asterisks) from control and Nanos3 NSCLC mice were stained for CC10, SPC and Sox2. Bars: 100 μm for the CC10 and SPC
pictures, and 200 μm for the Sox2 pictures
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and metastasis are the major causes of mortality in can-
cer patients, it is crucial to understand the molecular
mechanisms underlying the successive stages of cancer
progression in order to improve prevention, diagnosis
and treatment of cancer. We found that ectopic Nanos3
expression in the NSCLC mouse model chosen was as-
sociated with significantly shorter survival compared to
the genetically matched control mice lacking Nanos3
activity.
The reason for this aggravated pathology is unclear
because no metastases were observed in either case.
However, the lack of metastasis in this tumor model
might be explained by the short median observation
time that had to be selected for analysis of the transgenic
mice. A mouse lung cancer model based on the combin-
ation of a mutant KRas allele with a mutant TP53 allele
[48] showed a median survival of mice of 317 days,
whereas the median survival for female mice in our
NSCLC model was only 37 days. Remarkably, a
significant difference between the Nanos3 and control
NSCLC mice was seen only in female mice. Our NSCLC
models are reminiscent of lepidic carcinoma in humans,
which is more common in women [49, 50]. However,
this does not offer a full explanation for the sex differ-
ence we observed, since the survival of male and female
control NSCLC mice was similar. It rather seems that fe-
male mice are more prone to Nanos3-induced changes.
In general, the incidence and mortality of various can-
cers are associated with sex-specific disparities [51]. This
sex difference in cancer incidence is generally attributed
to regulation at the genetic/molecular level and to the
effect of sex hormones such as oestrogen and androgen.
It might be interesting to investigate whether gene ex-
pression levels differ between male and female Nanos3
NSCLC mice, but also the expression levels of Nanos3
interaction partners and Nanos3 mRNA targets should
be further investigated in male and female Nanos3
transgenic mice. Such thorough analysis might offer an
A
B
Fig. 7 The effects of Nanos3 on the malignant behavior of lung tumor-derived cells. a. Soft agar analysis. Cell cultures derived from the lungs of
a LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/− mouse (control NSCLC) and a Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/− mouse
(Nanos3 NSCLC) were grown in a soft agar solution at a density of 104 cells/ml. Parental and N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)
transformed HOS (human osteosarcoma) cell cultures were used as a negative and a positive control, respectively. Micrographs were quantified
with Volocity. Only colonies bigger than 100 μm2 were taken into account. Error bars, SEM; ns: not significant; **: P≤ 0.01. b. Allograft experiment.
Five athymic mice were each subcutaneously injected with 2.5 × 106 cells of a culture derived from the lungs of either a control NSCLC or a
Nanos3-overexpressing NSCLC mouse. Tumor volumes were measured twice a week. Each graph depicts the average tumor growth curve of
mice injected with the same cell culture
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explanation to the intriguing observed gender preference
in our mouse tumor lung model. Additionally, hormonal
contribution can also offer an explanation for the differ-
ential effects seen between Nanos3 NSCLC males and
females. A plausible explanation can be that Nanos3
function is suppressed by androgen receptor signalling
or that Nanos3 function is enhanced by oestrogen recep-
tor signalling. However, an initial analysis of GEO pro-
files did not reveal any significant changes in Nanos3
expression upon oestrogen or testosterone signalling. In
conclusion, further studies are needed to provide deeper
insight into the observed gender differences in our
NSCLC model. Interestingly, a similarly unexplained
shorter survival has been reported for female mice in a
model for metastatic lung adenocarcinomas based on
the combination of a mutant KRas allele and a mutant
TP53 allele [48]. Hence, other tumor models using the
Nanos3LSL alleles in combination with activated onco-
genes and/or inactivated tumor suppressor genes may
increase our knowledge of the in vivo roles of Nanos3 in
various cancers.
In our Nanos3LSL model, ectopic Nanos3 expression
seemed to affect the club cells in particular, as reflected
by significantly more hyperplastic bronchioles compared
to the lungs of control NSCLC mice. An important
element in cancer progression is the cross-talk between
the transformed epithelium and stromal cells. Therefore,
it is interesting that tumor-associated stromal cells were
eGFP-positive, and therefore most likely Nanos3-positive,
in the case of tumors derived from alveolar tissue, whereas
this could not be detected in tumors derived from bron-
chiolar tissue (Additional file 5: Figure S5). This observa-
tion needs more thorough investigation, and the use of
additional Cre mice in combination with the Nanos3LSL
Fig. 8 Differentiated metastases in lymph nodes of athymic mice injected with Nanos3-expressing tumor-derived cell cultures. Sections of H&E
stained lymph nodes of mice injected with LuTDco or LuTDNa3 cell cultures showed the presence of, respectively, infrequent atypical cells
lacking differentiation features (top panels, arrows), and prominent differentiated metastatic lesions (bottom panels). Lymph node sections were
stained for E-cadherin and pan-cytokeratin, providing proof for the epithelial origin and the obvious differentiation of the lymph node metastases.
Staining of lymph node sections with a GFP-specific antibody confirmed that the nodules in the lymph nodes of the LuTDNa3-injected mice
were derived from the transgene-positive primary tumors, as expected. The negative controls represent sections stained with secondary
antibodies only. Bars: 50 μm
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alleles may reveal important effects of ectopic Nanos3
induction in tumors.
The reason why female Nanos3 NSCLC mice died earl-
ier than the control mice could for instance be ascribed to
more severe bronchiolar hyperplasia in Nanos3-
expressing females, which might be detrimental to lung
function and hence lead to early death. A more advanced
stage, bronchiolar papilloma, was not observed in any of
the mice we examined. Such progression might have been
blocked by the high levels of Sox2 expression observed at
the bronchioles [52], which we confirmed in both normal
and hyperplastic bronchioles. Alveolar adenocarcinoma
formation turned out to be similar in both control and
Nanos3-expressing NSCLC mice. Although we have dem-
onstrated in our transgenic mouse models that Nanos3 is
potentially oncogenic in NSCLC, our in vivo data do not
support the previously proposed role of Nanos3 in E-
cadherin suppression and EMT induction in lung cancer
[27]. Thus, the exact mechanism controlled by Nanos3 in
the NSCLC tumors remains elusive.
Tumor-derived cell cultures from a control and a
Nanos3-expressing NSCLC mouse demonstrated
anchorage-independent growth, but LuTDNa3 cells
generated more and bigger colonies. A subcutaneous
allograft experiment with three control LuTDco and
three LuTDNa3 cell cultures revealed no reproducible
differences in ectopic tumor growth or lung metastasis
upon expression of Nanos3. However, large lymph node
metastases were only seen in mice injected with
LuTDNa3 cells. This observation points to a Nanos3
role in promoting lymph node metastasis. Remarkably,
these lymph node metastases showed obvious epithelial
tumor differentiation as evidenced by histology, pan-
cytokeratin and E-cadherin positivity. Expression ana-
lysis for EMT-related genes did not show any significant
differences between LuTDco and LuTDNa3 cell lines
and therefore suggested that other Nanos3-induced
pathways are involved in the increased lymph node
metastasis of LuTDNa3 cells. Intriguingly, NANOS3
overexpression in human NSCLC cell lines did enhance
their invasiveness by upregulating EMT [27]. However,
comparison of Nanos3 protein levels in mouse tumor-
derived LuTDNA3 cell lines and Nanos3 overexpressing
human NSCLC cell lines did not show higher Nanos3
protein levels in the human cell lines, which might ex-
plain the difference in Nanos3-induced EMT between
mice and men. In general, many differences occur be-
tween mice and men, including documented differential
effects of the immune system, life span, metabolism and
genomic imprinting [53]. More specifically, Nanos3 is an
RNA binding protein that recognizes its mRNA targets
by the presence of NRE or PBEs in the 3’UTRs of these
target genes. So, small sequence differences between the
3’UTRs of human and mouse transcripts can already
change Nanos3 binding properties and should be taken
into account when further exploring the observed
discrepancy between human tumors and mouse tumor
models.
Conclusions
The here described Nanos3LSL mouse model allows spa-
tiotemporally controlled ectopic expression of human
Nanos3. The natural testis/brain-specific expression of
this interesting protein and the fact that ectopic expres-
sion has been reported in various human cancers makes
Nanos3 a potential cancer/testis antigen (CTA) candi-
date. Our mouse model allows further analysis of the in-
fluence of ectopic Nanos3 expression in cancer and in
normal tissues. This system can also contribute much to
the discovery of physiologically relevant Nanos3 molecu-
lar interaction partners and Nanos3 mRNA targets. In
addition, it allows further investigation of the effect of
Nanos3 on germ cell development in mammals and the
pathways involved. Since ubiquitous expression of
Nanos3 turned out to be embryonically lethal, the
correct localization of Nanos3 protein expression seems
to be important in the mammalian embryo, as seen in
Drosophila. By using the Nanos3LSL mouse model, it will
be possible to further investigate the in vivo role of ec-
topic Nanos3 expression in NSCLC and other cancer
types.
Additional files
Additional file 1: Figure S1. The coding DNA sequence and the
corresponding Nanos3 protein sequence of the human NANOS3 gene.
After splicing, this gene is transcribed into two isoforms. The first intron
(first red horizontal arrow) is retained in the transcript encoding isoform
2, and encodes an in-frame peptide. (DOC 1602 kb)
Additional file 2: Figure S2. Part of the entry vector sequence
containing the AttL sites and the cDNA sequence of the Nanos3 entry
clone used to make the Nanos3 transgenic mice. (DOC 1392 kb)
Additional file 3: Figure S3. Generation by homologous recombination
into the ROSA26 locus of a transgenic mouse allowing conditional
ectopic expression of a human NANOS3 allele. The Gateway® Nanos3
entry clone was recombined with the ROSA26 destination vector
(pROSA26-DV1) [28], using LR clonase. The targeting vector was
replicated in bacteria, subsequently linearized (PvuI) and electroporated in
ES cells, where homologous recombination with the wild type (WT)
ROSA26 locus took place. Correctly targeted ES cells were selected
(resistance to geneticin [neomycin-resistant cells] and diphtheria toxin A
[DTA]) and screened by PCR and Southern blot analyses. The blue
(G1 and G2) and green (Nanos3_F and Nanos3_R) arrows represent the
sequencing primers used (Fig. 1d; Additional file 20: Table S1). The black
and red rectangles represent the 5′ probe and neo probe, respectively,
used for Southern blot analysis (Fig. 1c). The expected band sizes after
genomic DNA digestion of the WT or knock-in allele with the corre-
sponding restriction enzymes are indicated by the double-headed arrows.
Cre-mediated loxP recombination allows expression of Nanos3 and the
IRES-eGFP reporter under control of the ROSA26 promoter. The resulting
mice were genotyped using the primers represented by black (Rosa_F,
Rosa_R1 and Rosa_R2) and green arrows (Nanos3_F and Nanos3_R)
(Additional file 20: Table S1). LoxP sites are represented by triangles. SA,
splice acceptor site. (DOC 374 kb)
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Additional file 4: Figure S4. Epidermis-specific expression of the Nanos3
transgene. eGFP expression in skin sections from a Nanos3LSL/−;K5-Cre−/−
mouse and a Nanos3LSL/LSL;K5-Cre+/− mouse was analyzed by
immunohistochemical staining. Bottom panels show the same fields as top
panels, but with increased magnification. Bars, 100 μm. (PDF 3030 kb)
Additional file 5: Figure S5. eGFP expression in lungs of control and
Nanos3 NSCLC mice. Sections of adenocarcinomas (top panels) and
bronchioles (bottom panels) from control and Nanos3 NSCLC mice were
stained for eGFP. Expression is evident in both alveolar and bronchiolar
hyperplasia of Nanos3 NSCLC mice. Arrows point at stromal cells of an
adenocarcinoma tumor. From left to right, panels correspond to images
with increased magnification. Bars, 50 μm. (PDF 7230 kb)
Additional file 6: Figure S6. Microscopic images of H&E-stained lung
sections from control and Nanos3 NSCLC mice show different stages of
tumor progression in the alveolar spaces. Alveolar hyperplasia,
premalignant atypical adenomatous hyperplasia and adenocarcinoma
were observed in the alveolar spaces of both control and Nanos3 NSCLC
mice. Panels correspond to increasing magnification from left to right.
Bars, 50 μm. (PDF 8592 kb)
Additional file 7: Figure S7. Microscopic images of H&E-stained lung
sections from control and Nanos3 NSCLC mice show different stages of
tumor progression in the bronchiolar tissue. Focal and papillary
hyperplasia were observed in the bronchioles of both control and
Nanos3 NSCLC mice. Panels correspond to increasing magnification from
left to right. Bars, 50 μm. (PDF 6768 kb)
Additional file 8: Figure S8. The tumor percentage of the lungs is
comparable in control and Nanos3 NSCLC mice. Five H&E sections
throughout the complete lungs were used to measure the tumor mass by
scanning followed by appropriate image analysis as detailed in Methods.
Quantification was done with ImageJ. Error bars, SEM. (PDF 9 kb)
Additional file 9: Figure S9. CC10 expression in adenocarcinomas and
bronchioles of control and Nanos3 NSCLC mice. CC10 staining of lung
sections of adenocarcinomas (top panels) and bronchioles (bottom
panels) from control and Nanos3 NSCLC mice. Panels correspond to
increasing magnification from left to right. Bars, 50 μm. (PDF 6460 kb)
Additional file 10: Figure S10. SPC expression in adenocarcinomas and
bronchioles of control and Nanos3 NSCLC mice. SPC staining of lung
sections of adenocarcinomas (top panels) and bronchioles (bottom
panels) from control and Nanos3 NSCLC mice. Panels correspond to
increasing magnification from left to right. Bars, 50 μm. (PDF 6333 kb)
Additional file 11: Figure S11. Sox2 expression in adenocarcinomas
and bronchioles of control and Nanos3 NSCLC mice. Sox2 staining of
lung sections of adenocarcinomas (top panels) and bronchioles (bottom
panels) from control and Nanos3 NSCLC mice. Panels correspond to
increasing magnification from left to right. Bars, 50 μm. (PDF 6975 kb)
Additional file 12: Figure S12. E-cadherin expression in the bronchioles
and adenocarcinomas of NSCLC mice. A. E-cadherin staining of lung
sections from control (LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/−) and
Nanos3 (Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/−) NSCLC
mice. Bar, 200 μm. B. Both normal and hyperplastic bronchioles stained
positive for E-cadherin. Bar, 50 μm. (DOC 12361 kb)
Additional file 13: Figure S13. Vimentin expression in adenocarcinomas
and bronchioles of control and Nanos3 NSCLC mice. Vimentin staining of
lung sections of adenocarcinomas (top panels) and bronchioles (bottom
panels) from control and Nanos3 NSCLC mice showed similar vimentin
expression patterns for control and Nanos3 NSCLC mice. Panels
correspond to increasing magnification from left to right. Bars, 50 μm.
(PDF 6633 kb)
Additional file 14: Figure S14. Nanos3 and eGFP expression of primary
lung cancer cell cultures. Primary cell cultures derived from the lungs of a
control NSCLC mouse (LuTDco) and a Nanos3 overexpressing NSCLC
mouse (LuTDNa3) were tested for Nanos3 and eGFP expression by
western blotting (A) and RT-qPCR (B). Actin was used as a loading
control for western blot analysis. CNRQ, calibrated normalized relative
quantity, error bars, SEM; n = 3. Gene expression was normalized to
reference genes (rpl13A, ywhaz and sdha) using qbase+ (Biogazelle) [35].
(DOC 654 kb)
Additional file 15: Figure S15. Analysis of eGFP and NANOS3 mRNA
and protein expression in ectopic tumors (allografts) from control and
Nanos3-expressing lung tumor-derived cell cultures. Ectopic tumors were
dissected from athymic mice injected subcutaneously with cultured
primary lung cancer cells derived from either a LSL-KRasG12D;p53fl/fl;
CCSP-rtTA+/−;TetO-Cre+/− mouse (LuTDco) or a Nanos3LSL/−;LSL-
KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/− mouse (LuTDNa3). A. RNA ly-
sates were made from part of the ectopic subcutaneous tumors
originating from LuTDco or LuTDNa3 cell cultures. Each dot represents an
ectopic tumor from an athymic mouse injected with these cell cultures.
CNRQ, calibrated normalized relative quantity. Error bars, SEM; ns: not
significant, ****: P ≤ 0.0001. Gene expression was normalized to reference
genes (rpl13A, ywhaz and sdha) using qbase+ (Biogazelle) [35]. B. Protein
lysates from the allografts from the injected mice (M0 to M4) were
checked for Nanos3 and eGFP expression by western blotting. Actin was
used as a loading control. (DOC 768 kb)
Additional file 16: Figure S16. Epithelial differentiation in lymph node
metastasis of mice subcutaneously injected with LuTDNa3 cell cultures.
Lymph node sections were stained for E-cadherin (A) and pan-
cytokeratin (B), providing proof for the epithelial origin and the obvious
differentiation of the lymph node metastases. Panels correspond to
increasing magnification from left to right. Bars, 50 μm. (PDF 6514 kb)
Additional file 17: Figure S17. Lymph node metastasis of mice
subcutaneously injected with LuTDNa3 cell cultures. A. Sections of H&E
stained lymph nodes of mice injected with LuTDco or LuTDNa3 cell
cultures showed the presence of, respectively, infrequent atypical cells
lacking differentiation features (top panels), and prominent differentiated
metastatic lesions (bottom panels). B. Lymph node sections were stained
for eGFP and this confirmed that the metastatic lesions in the lymph
nodes of the LuTDNa3-injected mice were derived from the transgene-
positive primary tumors, as expected. Panels correspond to increasing
magnification from left to right. Bars, 50 μm. (PDF 7298 kb)
Additional file 18: Figure S18. EMT is not involved in the increased
lymph node metastasis by LuTDNa3 cells. A. Expression analyses of EMT-
related genes by qRT-PCR of transcripts in primary lung tumor-derived
cell lines LuTDco and LuTDNa3. This experiment revealed no significant
differences between LuTDco and LuTDNa3 cell lines for the expression
levels of the following genes, Cdh1, Vim, Cdh2, Fn, Snai1 and Zeb1. B.
Expression analyses of eGFP and Nanos3 by qRT-PCR in primary lung
tumor-derived cell lines LuTDco and LuTDNa3 showed specific eGFP and
Nanos3 expression in LuTDNa3 cell lines. CNRQ, calibrated normalized
relative quantity, error bars, SEM, ***: P ≤ 0.001 and ****: P≤ 0.0001 Gene
expression was normalized to reference genes (eef1a and hmbs) using
qbase+ (Biogazelle) [35]. (PDF 1358 kb)
Additional file 19: Figure S19. Comparison of Nanos3 expression levels
in lung tumor-derived mouse cell lines and established human lung
cancer cell lines. A. Protein levels of Nanos3 were detected by western
blotting. Top and middle panel represent lower and higher exposure
time, respectively, for Nanos3 detection. The Nanos3-specific bands are
indicated by the arrows. Actin expression acted as a loading control (bot-
tom panel). B. Quantification of Nanos3 levels in the blot of (A), normal-
ized against actin signals. (PDF 1411 kb)
Additional file 20: Table S1. A list of the primers used for genotyping.
(DOCX 14 kb)
Additional file 21 Completed ARRIVE Guidelines Checklist. (PDF 1093 kb)
Additional file 22: Animal Facility Procedures and Licenses of the
Inflammation Research Center, Ghent University and VIB, Ghent, Belgium.
(PDF 2414 kb)
Additional file 23: Table S2. A list of the RT-qPCR primers used.
(DOCX 14 kb)
Abbreviations
AAH: Atypical adenomatous hyperplasia; Alb-Cre: albumin Cre;
BAC: Bronchioloalveolar carcinoma; CC10: Club cell 10-kDa protein;
CCDS: Consensus coding sequence set; CCSP: Club cell secretory protein;
CNRQ: Calibrated normalized relative quantity; control NSCLC mice: LSL-
KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/− mice; Cre-negative
mice: Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre−/− mice;
Andries et al. BMC Cancer          (2019) 19:598 Page 15 of 17
CTA: Cancer/testis antigen; dox: Doxycycline; eGFP: enhanced green
fluorescence protein; EMT: Epithelial-mesenchymal transition; ES: Embryonic
stem; HOS: Human osteosarcoma; IRES: Internal ribosomal entry site; K5-
Cre: keratin-5 Cre; LSL: floxed STOP cassette; LuTDco: LSL-
KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/− tumor-derived primary culture;
LuTDNa3: Nanos3LSL/−;LSL-KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/− tumor-
derived primary culture; MET: mesenchymal–epithelial transition; MNNG: N-
methyl-N′-nitro-N-nitrosoguanidine; Nanos3 NSCLC mice: Nanos3LSL/−;LSL-
KRasG12D;p53fl/fl;CCSP-rtTA+/−;TetO-Cre+/− mice; neor: neomycin resistance;
NIM: NOT1 interacting motif; NRE: Nanos response elements; NSCLC: non-
small cell lung cancer; PBE: Pumilio-binding element; PFA: Paraformaldehyde;
PGK: Phosphoglycerine kinase; REML: Residual maximum likelihood; RT-
qPCR: quantitative reverse transcription polymerase chain reaction;
rtTA: reverse tetracycline transactivator; SEM: Standard error of mean;
SPC: Surfactant Protein C; tetO: tetracycline operator; UTR: Untranslated
region; Zf-nanos: (CCHC)2 zinc-finger domain of Nanos proteins
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